US Markets

U.S. tells cannabis companies not to advertise disease treatments without science

Credit: REUTERS/MIKE SEGAR

The top U.S. consumer and trade regulator said on Tuesday it had warned three companies selling products infused with cannabidiol that it was illegal to advertise that such products could fight disease without providing credible scientific evidence.

WASHINGTON, Sept 10 (Reuters) - The top U.S. consumer and trade regulator said on Tuesday it had warned three companies selling products infused with cannabidiol that it was illegal to advertise that such products could fight disease without providing credible scientific evidence.

In recent years, the chemical derived from the cannabis plant, commonly called CBD, has been touted as alleviating countless physical ailments.

The Federal Trade Commission said the three unidentified companies claimed, without providing substantiation, that CBD can treat more than two dozen conditions including cancer, Alzheimer's, multiple sclerosis, schizophrenia, epilepsy, diabetes, psoriasis, and AIDS.

The companies, which sell oils, tinctures, capsules, gummies and creams, have 15 days to inform the FTC about how they will address the warning.

(Reporting by Lisa Lambert, Editing by Rosalba O'Brien)

((lisa.lambert@thomsonreuters.com; +1 202 898 8328; Reuters Messaging: lisa.lambert.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

Commodities

Latest Markets Videos

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More